Drug-Induced Liver Injury Network (DILIN)
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) created the Drug-Induced Liver Injury Network to collect and carefully analyze cases of liver injury caused by prescription and non-prescription drugs, nutritional supplements and herbal remedies.
NIDDK recognizes that liver injury due to prescription and non-prescription medications is a medical, scientific, economic and public health problem of increasing frequency and importance in the U.S., and is the most common cause of acute liver failure. There is a critical need to develop an improved means of detecting, defining and studying drug-induced liver injury in the U.S.
The goals of the program include:
- developing better diagnostic instruments to assess the causality in drug-induced liver injury
- expanding the DILIN as a national and international resource for basic and clinical researchers and clinical practitioners in drug-induced liver injury
- developing educational materials that will aid researchers and clinical practitioners in the diagnosis, categorization, and management of drug-induced liver injury
- facilitating the development of innovative approaches to the prevention, control, management and treatment of drug-induced liver injury
Since enrollment began in May 2004, more than 600 cases of drug-induced liver injury have been characterized and biosamples collected. This includes comprehensive clinical, laboratory, and imaging data, making DILIN an important resource for health care providers. Additional details on DILIN are available at the project website.
Get involved. Partner with us.
To learn more about partnership opportunities with the Drug Induced Liver Injury Network project, contact us:
Julie Wolf-Rodda, Director of Partnership Development
Phone: (301) 402-5311
E-mail: jwolf-rodda [at] fnih [dot] org
For more information on individual giving opportunities, please contact: